Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen hydrogel

Narges Mahmoodi1, Jafar Ai2, Zahra Hassannejad3, Somayeh Ebrahimi-Barough2, Elham Hasanzadeh4, Houra Nekounam5, Alexander R. Vaccaro6 & Vafa Rahimi-Movaghar1

Spinal cord regeneration is limited due to various obstacles and complex pathophysiological events after injury. Combination therapy is one approach that recently garnered attention for spinal cord injury (SCI) recovery. A composite of three-dimensional (3D) collagen hydrogel containing epothilone B (EpoB)-loaded polycaprolactone (PCL) microspheres (2.5 ng/mg, 10 ng/mg, and 40 ng/mg EpoB/PCL) were fabricated and optimized to improve motor neuron (MN) differentiation efficacy of human endometrial stem cells (hEnSCs). The microspheres were characterized using liquid chromatography-mass/mass spectrometry (LC-mas/mas) to assess the drug release and scanning electron microscope (SEM) for morphological assessment. hEnSCs were isolated, then characterized by flow cytometry, and seeded on the optimized 3D composite. Based on cell morphology and proliferation, cross-linked collagen hydrogels with and without 2.5 ng/mg EpoB loaded PCL microspheres were selected as the optimized formulations to compare the effect of EpoB release on MN differentiation. After differentiation, the expression of MN markers was estimated by real-time PCR and immunofluorescence (IF). The collagen hydrogel containing the EpoB group had the highest HB9 and ISL-1 expression and the longest neurite elongation. Providing a 3D permissive environment with EpoB, significantly improves MN-like cell differentiation and maturation of hEnSCs and is a promising approach to replace lost neurons after SCI.

Spinal cord injury (SCI) is a very common traumatic event and is mainly caused by falls and motor vehicle accidents (MVAs)1.2. Extensive neuron loss and axon degeneration are common cellular findings at the lesion site following SCI, leading to severe disability in patients due to limited neuronal regeneration and recovery3–5. Currently, no therapy is available for complete functional recovery after SCI6,7, however, advances in medical care can increase life expectancy in patients with SCI and reduce their families’ financial burden8,9. As a growing research area, using various stem cells has been garnered great attention for nerve tissue regeneration through cell differentiation for lost cell replacement, anti-inflammatory effects, and neurotrophic factor secretion4,10. However, stem cell therapy utility is usually limited given low cell survival and uncontrollable cell differentiation at the site of injury4. SCI also leads to complex, destructive biological processes that may continue up to one year after injury11. Thus, to reach the full potential of stem cells, a synergistic effect through combination therapy is necessary12.

1Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. 3Pediatric Urology and Regenerative Medicine Research Center, Tissue, Cell and Gene Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 4Immunogenetics Research Center, Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran. 5Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. 6Department of Orthopedic Surgery, Rothman Institute, Thomas Jefferson University, Philadelphia, PA, USA. *email: v_rahimi@tums.ac.ir
One of the most promising stem cells for SCI therapy is a group of adult multipotent mesenchymal stem cells (MSCs), which can be induced to different cell types13–15. Human endometrial stem cells (hEnSCs) as a MSCs have considered attention for cell therapy and tissue engineering16–20. Interestingly, in a recent study, a comparison between hEnSCs and human bone marrow stem cells (hBM-MSCs) showed a better motor neuron (MN) differentiation potential for hEnSCs21. Improvement in differentiating stem cells into specialized neurons is one solution for replacing damaged or lost cells, thereby leading to potential functional recovery2.

Motor neurons are a type of nerve cells that end at myocytes and transfer nerve impulses to control voluntary muscle movements. After SCI, there is a substantial loss of motor neurons and interneurons in the spinal cord tissue22, while endogenous regeneration of neurons and revival of motor function is limited23. A spectrum of illnesses such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) can also lead to motor neuron degeneration24. To cure these illnesses, researchers are trying to develop methods to produce MN-like cells from stem cells24. MN-derived cells can also be utilized for MN-modelling and drug-screening assays25,26. MTs disruption and disorganization are characteristics of damaged nerve cells after SCI27,28. Likewise, MTs disorganization has been noticed as a primary etiology of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases29,30, and, recently, microtubule-stabilizing agents (MSAs) have been considered in the treatment strategy of these disorders31.

Epitheliotin B (EpoB), also known as patupiline, is a macrolide derived from myxobacteria Sorangium cellulosum and an MSA that can cross the blood–brain barrier (BBB). A recent study showed that EpoB can induce axon regeneration and elongation in damaged nerve cells and decrease scar formation after SCI in rodents32–34. These studies, however, used systemic administration of drugs, and the possible side effects and short half-life limit us from reaching maximal efficacy. Moreover, various medical interventions. A biocompatible and biodegradable delivery system can offer sustained release of therapeutic agents and thus increase their effectiveness without using excessive invasive surgical techniques35. For the delivery of drugs, they can be encapsulated into biomaterial-based microspheres for sustained release, which provides in situ sustained release35.

In the field of tissue engineering, utilizing naturally derived hydrogels have gained momentum for localized drug delivery application for presenting easily mimicking and integrating with native tissues, for similar characteristics to soft tissues, and their excellent recognition by different cell types36,40. Among various natural-based hydrogels, collagen is the major protein of the extracellular matrix (ECM) in many mammalian tissues36. Collagen is distinguished being a highly biocompatible cellular growth supporter and is noncytotoxic37. Though collagen has been extensively used in the clinic and tissue engineering for various applications38, its high degradation degree, mechanical instability, and thermosensitivity have led researchers to add other polymers or cross-linkers to achieve more desirable features39,40. Therefore, in this study, we chose a cross-linking approach to improve hydrogel stability while preserving the utility of collagen hydrogel as an appropriate three-dimensional (3D) structure for enhancing cell proliferation and differentiation. Many different kinds of cross-linked hydrogels have been used as 3D scaffolds and drug delivery systems for soft tissue engineering, including corneal, cartilage, skin, tendon, and peripheral and central nervous tissues38–40. Proanthocyanidin (PA) is a natural polyphenolic oligomeric flavonoid found in flowers, vegetables, fruits, seeds, nuts, and barks41. PA is a promising cross-linker with a variety of biological activities, including anti-inflammatory, anti-tumor, antioxidant, anti-bacterial, anti-calcification. PA provides biocompatible cross-linked hydrogels and has non-toxicity properties, unlike common cross-linkers such as formaldehyde and glutaraldehyde42–55. Evidence shows that combination strategies achieve greater results than using each component separately by addressing various aspects of SCI pathophysiology31. Accordingly, in this study, we aimed to enhance the differentiation potential of hEnSCs into MN-like cells and axonal elongation using the signaling molecules sonic hedgehog (SHH) and retinoic acid (RA), and also by providing a hydrogel-based 3D microenvironment capable of controlling the release of EpoB using PCL microspheres.

Materials and methods
Isolation and culture of human endometrial stem cell (hEnSC). hEnSCs were isolated according to a previous study56. The collection of discarded endometrium biopsies from patients was achieved via the informed consent from the patients/legal guardian. All methods were performed in accordance with the relevant guidelines and regulations of Tehran University of Medical Sciences and approved by the university’s ethical committee (code: IR.TUMS.REC.1394.1137). Briefly, biopsies of endometrium were washed with phosphate-buffered saline (PBS; Sigma, P4417) containing 2–3% amphotericin B and penicillin/streptomycin, were cut into small pieces and digested with collagenase type I (1 mg/mL, Sigma-Aldrich) in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM-F12; Invitrogen) for 2 h at 37 °C. The enzyme was then neutralized by adding a complete medium composed of DMEM-F12 with 10% fetal bovine serum (FBS; Gibco, 10270-106). Subsequently, the samples were passed through 70 μm and 40 μm filters and were centrifuged at 1200 rpm for 5 min. After the supernatant was removed, the pellets of cells was resuspended in a complete medium containing 10% FBS and 1% penicillin/streptomycin. The cell suspension was transferred to 6-well cell culture plates and incubated in a humidified chamber at 37 °C with 5% CO2. The medium was exchanged every 3 days. Three or four passages of hEnSCs were used for all of our experiments.

Flow cytometry. To confirm the identity of the isolated cells, passage three cells were used for flow cytometry BD FACSCalibur (BD Biosciences, USA). The evaluated markers were as follows: endometrial stem cell...
Green fluorescent protein (GFP) labeled hEnSCs. Based on previous studies, lentivirus (second-generation) was used for GFP gene transduction of hEnSCs and HEK293-T cells. We also labeled HEK293-T as the fluorescein isothiocyanate.

Table 1. Markers for hEnSCs identification. PE phycoerythrin, PerCP peridinin chlorophyll protein, FITC fluorescein isothiocyanate.

| Markers for hEnSCs | Cell surface marker | Percentage (%) | Antibody | Catalog number |
|--------------------|--------------------|----------------|----------|----------------|
| Endometrial stem cell marker | CD146 | 89.1 | PE-conjugated anti-CD146 | BD Biosciences, 561013 |
| Mesenchymal stem cell marker | CD44 | 98.5 | FITC-conjugated anti-CD44 | Immunostep, 44F2-100T |
| Hemopoietic stem cell marker | CD45 | 0.3 | FITC-conjugated anti-CD45 | BD Biosciences, 560976 |
| Endothelial marker | CD31 | 0.3 | PE-conjugated anti-CD31 | Immunostep, 31PE-100T |

marker (CD146), mesenchymal stem cell markers (CD44, CD90, and CD105), hematopoietic stem cell markers (CD34 and CD45), and endothelial stem cell markers (CD31).

The cells were washed three times with Hank’s Balanced Salt Solution (HBSS) and 2% bovine serum albumin (BSA; Sigma, A7030) and then were incubated with a specific antibody (Table 1) at concentrations recommended by the respective manufacturers (for 1 h). Data were evaluated by FlowJo Version 7 software.

Microsphere fabrication and sterilization. The oil in water (o/w) single emulsion method was used to synthesize the EpoB-loaded PCL microspheres. First, 250 mg of polycaprolactone (PCL; Sigma, 363170) was dissolved in 2 mL of dichloromethane (DCM; Sigma, 32222) using a magnet stirrer (Heidolph, Hei-Tec) for 25 min at 35 °C. Three groups of EpoB-loaded PCL microspheres were fabricated by adding 0.625 µg, 2.5 µg, and 10 µg of EpoB (Abcam, 152044-54-7) to the PCL solution for an EpoB loading of 2.5 ng/mg, 10 ng/mg, and 40 ng/mg (EpoB/PCL), respectively. Unloaded microspheres were synthesized through the elimination of EpoB from the formulation. 2 mL of pure ethanol (Merck, 111727) was added to the solution while stirring, and 2 mL of 2% (w/v) polyvinyl alcohol (PVA) (Sigma, 363170) solution was slowly added drop by drop without disrupting the boundary layer. Then, the solution was mixed and emulsified for 12 s using a vortexer (Heidolph) and instantly added to a 100 mL beaker containing 50 mL of 0.3% (w/v) polyvinyl alcohol (PVA) solution at 35 °C. To evaporate the organic solvent, the solution was stirred with a 3 cm × 0.5 cm round magnetic stirring bar at 500 revolutions per minute (rpm) for 4 h in a 100 mL beaker. Since EpoB is light sensitive, the entire fabrication process was performed in a dark room. It is worth noting, due to the importance of mentioning parameters such as magnetic bar’s length, diameter, and the size of cylindrical container for having a reproducible particle synthesis method, these specifications were mentioned above.

After synthesizing 2.5 ng/mg, 10 ng/mg, and 40 ng/mg (w/w, EpoB/PCL) EpoB microspheres, the suspension of each group was centrifuged at 4000 rpm for 10 min at room temperature to separate the microparticles and supernatant. The amount of EpoB in the supernatant was evaluated as the extent of unencapsulated EpoB using liquid chromatography-mass/mass spectrometry (LC-Mas/Mas; HPLC Alliance 2695 Waters, Quattro Micro API micromass micromass) with a C18 column (4.8 × 150 mm, 5 µm, Agilent Zorbax XDB). The standard solutions of EpoB and each microsphere sample were loaded to LC-MS/MS and first eluted with methanol: water (40:60) for 5 min at the speed of 0.5 mL/min and then

Determination of encapsulation efficiency (EE). After synthesizing 2.5 ng/mg, 10 ng/mg, and 40 ng/mg (w/w, EpoB/PCL) EpoB microspheres, the suspension of each group was centrifuged at 4000 rpm for 10 min at room temperature to separate the microparticles and supernatant. The amount of EpoB in the supernatant was evaluated as the extent of unencapsulated EpoB using liquid chromatography-mass/mass spectrometry (LC-Mas/Mas; HPLC Alliance 2695 Waters, Quattro Micro API micromass micromass) with a C18 column (4.8 × 150 mm, 5 µm, Agilent Zorbax XDB). The standard solutions of EpoB and each microsphere sample were loaded to LC-MS/MS and first eluted with methanol: water (40:60) for 5 min at the speed of 0.5 mL/min and then

Scanning electron microscopy (SEM). To evaluate the size and morphology of microspheres, a ZEISS DSM 960A Oberkochen (Germany) scanning electron microscope (SEM) was used. Microspheres were sputter-coated with gold (20 kV for 4 min), and after imaging, their diameters were measured as the extent of unencapsulated EpoB using liquid chromatography-mass/mass spectrometry (LC-Mas/Mas; HPLC Alliance 2695 Waters, Quattro Micro API micromass micromass) with a C18 column (4.8 × 150 mm, 5 µm, Agilent Zorbax XDB). The standard solutions of EpoB and each microsphere sample were loaded to LC-MS/MS and first eluted with methanol: water (40:60) for 5 min at the speed of 0.5 mL/min and then
methanol:water (95:5). The retention time of EpoB was 9 min. The samples were quantified based on the standard curve of EpoB (all samples were run in triplicate).

The encapsulation efficiency (EE) of EpoB in the PCL microparticle was determined as the following formula:

$$EE\% = \frac{\text{Total Epo B added (ng) } - \text{Unbound Epo B (ng)}}{\text{Total Epo B used (ng)}} \times 100\%$$

**EpoB release measurement.** 10 mg of 2.5 ng/mg, 10 ng/mg, and 40 ng/mg (w/w, EpoB/PCL) EpoB-loaded microspheres were suspended in 1.5 mL of PBS in a Costar® Spin-X® centrifuge tube filter (0.22 µm pore CA membrane; Corning, 8160). The microspheres were placed in the above chamber containing the filter, filled with 0.5 mL PBS, and the tube filled with 1 mL PBS. These tubes were used to prevent microspheres from being mistakenly collected at the time of sampling. The Costar® Spin-X® centrifuge tubes were then placed on a shaker (Lab Tech, LSI-3016R) at 100 rpm and incubated at 37 °C. For the in vitro study, to simulate the conditions of exchanging the culture medium, in the release test, the PBS was exchanged every 2 days. Three samples were considered for each time point (7-time points: 1 and 18 h and 1, 3, 6, 14, and 21 days). The PBS of each sample was collected entirely at each time point. First, the PBS of the tubes was collected (not the above chamber that contained the filter), then each chamber was centrifuged with its tube at 4000 rpm for 5 min until the PBS in the chamber inter the tube and could be collected. The PBS was then stored at −80 °C and protected from light until all the samples were collected for further analysis.

The amount of EpoB was determined by using LC-Mas/Mas. In addition, to better identify the drug amount, the samples were first concentrated six times. For this purpose, each 1.5 mL samples were freeze-dried for 24–48 h and then dissolved in 200 µL deionized water and 50 µL methanol. For cell culture application, the candidate microspheres were then sterilized by air plasma (Harrick, PDC-32G) on low power for 30 s.

**Determining the effect of microspheres on cell viability and proliferation.** According to experimental release results, the microsphere containing 2.5 ng/mg (EpoB/PCL) was selected as the candidate microsphere for this study, referred to as Mic-2.5-EpoB in this text. To determine the biocompatible concentration of microparticles for hEnSCs culture, first, different concentrations of unloaded PCL microspheres (5, 10, 15, and 40 mg/mL) were used by indirect MTT assay for 24, 48, and 72 h. After evaluating their results, a second indirect MTT assay was performed for Mic-2.5-EpoB for 24, 48, and 72 h to assess the effect of the loaded microsphere on viability and proliferation of hEnSCs. For both MTT assays, 2 × 10^5 hEnSCs were seeded in each 24-well cell culture plate containing 500 µL of complete medium and incubated at 37 °C, 5% CO₂ for 24 h. Then, the cell culture was replaced with extract solutions of the microspheres and incubated at 37 °C, 5% CO₂ for 24, 48, and 72 h. The microsphere extract solutions of the (5, 10, 15, and 40 mg/mL unloaded PCL microspheres and Mic-2.5-EpoB) in complete medium (DMEM-F12 + 10% FBS) were collected every 24 h (each group was performed in triplicate). For each time point, the medium was removed and replaced with 5 mg/mL tetrazolium (Sigma) in PBS (MTT solution) and incubated for 3 h at 37 °C, 5% CO₂. The optical density (OD) of formazan dye dissolved in dimethyl sulfoxide solution (DMSO) was obtained using an ELISA microplate reader (Gen5, Power Wave XS2, BioTek, USA) at 590 nm. The following formula calculated the cell viability percent of hEnSCs:

$$\%\text{Cell Viability} = \frac{\text{OD treated well}}{\text{OD control well}} \times 100\%$$

The MTT test was also used to determine the permissible particle limit in the cell culture for hEnSCs.

**Fabrication of collagen hydrogels.** Collagen type I was extracted from rat tails following a previously developed method⁵⁹. Collagen was sterilized through dialysis with 1% chloroform (Merck) using dialysis bags with a molecular cut of 6–8 kDa (SpectraPor, 132660) for 1 h at 4 °C. Collagen hydrogels were fabricated using a ratio of 8:1:1 of sterile collagen solution:10 × DMEM/F12:HSS buffer. The HSS buffer was prepared by dissolving 4.77 g HEPES and 2.2 g sodium bicarbonate in 100 mL of 0.5 M sodium hydroxide. For gelation, 500 µL of the prepared mixture was poured into 24-well cell culture plates and incubated at 37 °C for 1 h. Two final concentrations of collagen were used to fabricate the hydrogels: 2 mg/mL and 4 mg/mL.

To improve stability of the hydrogel, collagen hydrogels were also cross-linked using different concentrations of proanthocyanidin (Grape Seed, Proanthocyanidins, Shari®, Iran) in PBS, including 0.25% PA, 0.5% PA, and also 0.5% PA with 0.05 M Ca(OH)₂ (PA-Ca(OH)₂). In the last formulation, we used Ca(OH)₂ based on evidence indicating that Ca(OH)₂ facilitates the penetration of PA and collagen cross-linking⁵². After one-hour incubation of collagen solutions (2 mg/mL and 4 mg/mL) at 37 °C, 100 µL of PA solution was added, and the cell culture plates were further incubated for 48 h at room temperature in a sterile condition. Then, the hydrogels were washed with PBS three times to remove the excess crosslinkers. The specifications of hydrogel preparation are summarized by code in Table 2.

**Fabrication of collagen hydrogel containing EpoB-loaded microspheres.** To mix EpoB microspheres with collagen hydrogel for 3D culture application, candidate microspheres were coated with a dilute sterilized collagen solution (0.5 mg/mL) overnight at 4 °C. Before coating, the collagen solution was neutralized using a 1 N solution of filter-sterilized NaOH in water (syringe-filter 0.22-µm membrane), bringing the pH to around 7.4.
Cell seeding within the collagen hydrogels. In each 24-well culture plate, 50 µL of 1 × 10^5 hEnSCs in complete medium (DMEM-F12 and 10% FBS) was slowly added to collagen hydrogels and incubated for 30 min at 37 °C for cells attachment. Then, 150 µL complete medium was added to each well.

Cell morphology, attachment, and proliferation on the collagen hydrogels. Fluorescent microscopy. To study cell adhesion, morphology, and proliferation in collagen hydrogels, two types of GFP-labeled cells (HEK293-T and hEnSCs) were used. In each 24-well cell culture plate, 1 × 10^5 cells were seeded and incubated at 37 °C with 5% CO₂. To observe the cells, an Olympus (BX51, Japan) immunofluorescence microscope was used.

Scanning electron microscope. An SEM (AIS2300C SEI, Korea) at 20 kV was used for investigating cell attachment of hEnSCs on collagen, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB hydrogel scaffolds, after 48 h of cell seeding. The SEM was also performed for observing the surface morphology of collagen, 2-Col/PA, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB hydrogel scaffolds. The medium of each 24-well was discarded, and each specimen was washed with PBS and fixed with Karnovsky's fixative solution (consisting of 2% paraformaldehyde and 2.5% glutaraldehyde) at room temperature for 1 h. Subsequently, the prepared samples were washed twice with PBS and then dehydrated with a graded ethanol series of 30, 50, 70, 90, 95, and 100%. Afterward, to examine the specimens via SEM, the samples for cell attachment study were first dried on an aluminum foil at room temperature, and the samples for surface morphology study were freeze-dried for 48 h, then each sample was under vacuum and finally coated with gold sputtering.

Hydrogel biodegradation degree. We assessed the degradation degree of collagen, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB hydrogels based on their weight loss in DMEM-F12 medium at 37 °C. The DMEM-F12 medium was exchanged every 3 days. Hydrogel weight alterations were evaluated over 14 days (all time points were run in triplicate). The degradation degree was calculated using the following equation:

\[
\text{Degradation degree} = \frac{(W_0 - W_t)}{W_0} \times 100\%
\]

where, \(W_0\) and \(W_t\) indicate the weight of hydrogels before and after immersing in medium, respectively.

Swelling degree. The swelling degree of the hydrogel scaffolds, including collagen, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB were measured for 96 h. The hydrogels were allowed to swell in DMEM-F12 at 37 °C. Each time point was performed in triplicate.

The weight of the wet samples was measured, and the swelling degree was obtained via the following formula:

\[
\text{Swelling degree} = \frac{(W_t - W_0)}{W_0} \times 100\%
\]

where, \(W_0\) and \(W_t\) are the weight of the primitive hydrogel and the weight of the swollen hydrogel, respectively.

ATR-FTIR spectroscopy. Proanthocyanidin (PA; GrapeSeed, Shari’, Iran) blended tablets were first dissolved in water. Then the precipitated additives of the tablet were removed and filtered through a 0.22 μm membrane. The samples (PA, Collagen, 2-Col/PA, and 2-Col/PA-CH) were freeze-dried for 48 h and then analyzed using an ATR accessory (Nicolet Avatar, Thermo Fisher Scientific, Waltham, MA, USA).

Differentiation of hEnSCs into motor neuron-like cells within 3D collagen hydrogels containing EpoB-loaded microspheres. Differentiation of hEnSCs was conducted in a three-step approach using 24-well cell culture plates with different experimental groups, including collagen hydrogel without Mic EpoB (2-Col/PA-CH), collagen hydrogel with Mic EpoB (2-Col/PA-CH/Mic EpoB), tissue culture plate (TCP; hEnSCs differentiation without Mic EpoB and collagen hydrogel), and control (undifferentiated hEnSCs). 2 × 10^5 hEnSCs in complete medium (DMEM/F12 and 10% FBS) at passage three were seeded on different substrates and incubated at 37 °C and 5% CO₂. After 24 h, in step one, the complete medium was replaced with a pre-induction (PrI) medium, and cells were incubated for 24 h. In step two, the PrI medium was exchanged with the induction medium, and cells were incubated for 7 days (the medium was exchanged after 3 days). In step three,
the induction medium was replaced with a maturation medium, and incubation was continued for an additional 7 days (the medium was exchanged after 3 days). All procedures and reagents are summarized in Table 3.

**Immunofluorescence (IF) staining.** All samples were fixed using 4% paraformaldehyde in PBS for 30 min at room temperature and then permeabilized using 0.2% Triton X-100/PBS. The cells were blocked using 5% BSA/PBS for 45 min at room temperature and incubated overnight with primary antibodies at 4 °C (Table 4). Then, each sample was washed three times with PBS/Tween 20 (0.1%, Sigma). Secondary antibodies were added, and samples were kept in the dark for one hour at room temperature. Cells were again washed with PBS/Tween 20 (0.1%) three times. Cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, D8417). For the negative control group, only secondary antibodies were used.

**RNA extraction and cDNA synthesis.** Total RNA extraction was conducted using RNX Plus™ low copy RNA isolation (CinnaGen, Iran, EX6101), chloroform, isopropl alcohol, and 75% ethanol. The purity and quantity of each extracted RNA were assessed using a Nanodrop spectrophotometer (Thermo Scientific, USA). cDNA synthesizing was conducted using PrimeScript™ RT Reagent Kit (Takara, RR037A) following the manufacturer’s instruction (Thermocycler schedule: 15 min at 37 °C, 5 s at 85 °C).

**Real-time RT-PCR for gene expression analysis.** All primers were obtained from Qiagen (Germany) (Table 5). RealQ RNA quantitative measurement was evaluated using Plus 2 × Master Mix Green (AMPLIQON, 5000850-1250) on a real-time thermocycler (Rotor-Ge®ne Q, Corbett Life Science, USA) (Table 6). PCR product specificity was evaluated by confirming a single peak in the melting curve analysis. All experimental samples were performed three times in duplicate. *RPL13A* was selected as a housekeeping gene, and each gene fold-

---

### Table 3. The procedure and reagents used for differentiation of hEnSCs into motor neuron-like cells on 3D collagen hydrogels with or without EpoB-loaded PCL microspheres or cell culture plates.

| Step | Differentiation medium | Ingredients | Catalog number | Duration |
|------|-------------------------|-------------|----------------|----------|
| 1    | Pre-induction (PrI) medium | DMEM/F12 (1:1) | Invitrogen, 32500-035 | 1 days |
|      |                         | 20% FBS     | Gibco, 10270-106 |
|      |                         | 2% B-27 supplement | Gibco, 17504-044 |
|      |                         | 100 μM 2-Mercaptoethanol | Sigma, M3148 |
|      |                         | 250 μM isobutylmethylxanthine (IBME) | Sigma, I5879 |
|      |                         | 10 ng/mL fibroblast growth factor 2 (FGF2) | Sigma, SRP4037 |
| 2    | Induction medium (exchanged after 3 days) | DMEM/F12 (1:1) | Invitrogen, 32500-035 | 7 days |
|      |                         | 0.2% B-27 supplement | Gibco 17504-044 |
|      |                         | 100 ng/mL sonic hedgehog (SHH) | Sigma, SRP3156 |
|      |                         | 0.01 μM retinoic acid (RA) | Sigma, R2625 |
| 3    | Maturation (survival) medium (exchanged after 3 days) | DMEM/F12 (1:1) | Invitrogen, 32500-035 | 7 days |
|      |                         | 0.2% B-27 supplement | Gibco 17504-044 |
|      |                         | 100 ng/mL glial cell-derived neurotrophic factor (GDNF) | Sigma, G1777 |
|      |                         | 200 ng/mL brain-derived neurotrophic factor (BDNF) | Sigma, SRP3014 |

### Table 4. Primary and secondary antibodies were used for immunofluorescence staining.

| Antibody/stain | Catalog number | Dilution |
|----------------|----------------|----------|
| **Primary antibody** | | |
| Anti-beta-III-tubulin antibody (Tuj-1) (rabbit monoclonal) | Abcam, ab68193 | 1:200 |
| Anti-Islet-1 (mouse monoclonal) | Abcam, ab86472 | 1:200 |
| Anti-choline acetyltransferase (CHAT; mouse monoclonal) | Santa Cruz, sc-55557 | 1:200 |
| Anti-nestin (NES; mouse monoclonal) | PadzaCo, MN105 | 1:200 |
| Anti-Homeobox 9 (HB9; mouse monoclonal) | Santa Cruz, sc-515769 | 1:50 |
| **Secondary antibody** | | |
| Goat anti-rabbit IgG (H + L) cross-adsorbed secondary antibody, Alexa Fluor 488 | Gibco, A-11008 | 1:500 |
| Goat anti-mouse IgG (H + L) highly cross-adsorbed secondary antibody Alexa Fluor 594 | Gibco, A-11032 | 1:700 |
| **Nuclear stain** | | |
| 4′,6-Diamidino-2-phenylindole (DAPI) | Sigma-Aldrich, D8417 | 1:1000 |
change was calculated relative to RPL13A based on relative quantitation evaluation via the ΔΔCT method, using the $2^{-ΔΔCT}$ relative expression equation. A summary of the different steps of the study is shown in Fig. 1.

**Analysis and quantification of neurite extension.** Analysis of neurite extension was investigated using an inverted phase-contrast microscope (Olympus, Japan) attached to a digital camera (DP50). For each experimental group, five random representative areas were selected for neurite length measurement using ImageJ software.

**Statistical data analysis.** Data were analyzed using SPSS 21 software. One-way ANOVA and Dunnett’s two-tailed t-test (DUNNETT) were employed to evaluate the statistical significance of differences between the control and all experimental groups.

**Ethics declarations.** Ethical approval for collecting biopsy disposal of patients human endometrial was obtained from the Ethics Committee of Tehran University of Medical Sciences (code: IR.TUMS.REC.1394.1137). An informed consent was obtained from patients/legal guardians according to Tehran University of Medical Sciences guidelines. All methods were performed in accordance with the relevant guidelines and regulations.

### Results

**Characterization of hEnSCs derived from endometrium.** The hEnSCs were positive for mesenchymal stem cell markers CD44 (98.5%), CD90 (98.4%) and CD105 (98.4%), endometrial stem cell marker CD146 (89.1%). hEnSCs were also negative for hematopoietic CD45, CD34, and endothelial CD31 markers (Fig. 2a).

**Cell GFP transduction.** Two types of cells, HEK293-T, and hEnSCs were labeled. As shown in Fig. 2b, cells were effectively transduced by GFP-encoding lentiviral particles. The GFP-positive cells were observed by fluorescent phase-contrast microscopy and used to assess cell adhesion and proliferation within hydrogels.

**EpoB-loaded PCL microsphere characterization.** Scanning electron microscope. The morphology of the fabricated microspheres was assessed using SEM. SEM images indicated a round shape with some clustering and smooth surface. The diameters of 2.5, 10, and 40 ng/mg EpoB/PCL microspheres were 3.143 ± 1.485 µm, 4.747 ± 3.434 µm, and 2.931 ± 1.543 µm, respectively. Compared to the EpoB/PCL microspheres, the unloaded microspheres were larger, with a diameter of 6.570 ± 4.833 (P < 0.001) (Fig. 3a–h).

**Encapsulation efficiency.** The encapsulation efficiencies (EE) for different loading concentrations of EpoB are shown in Table 7. A greater EE was obtained in PCL microspheres with higher EpoB loading levels, indicating that the initial concentration of EpoB can potentially affect EE of EpoB in PCL microspheres using the single emulsion fabrication method.
EpoB release. As shown in Fig. 3i, there was a burst release in the initial first 24 h for all groups, followed by a slower gradual release for 2.5 and 10 ng/mg EpoB/PCL microspheres, which reached a plateau. However, compared to 2.5 and 10 ng/mg EpoB/PCL microspheres, the 40 ng/mg EpoB/PCL microspheres maintained a higher release rate over 21 days, indicating that the release rate is influenced by the amount of EpoB encapsulated in the microspheres. According to the EpoB release results, 2.5 ng/mg was selected due to its appropriate sustained release dosage for neuronal differentiation.

Proliferation and viability assessment of microspheres. To find the permissible limit, the effect of four different concentrations of unloaded PCL microspheres (unloaded Mic: 5, 10, 15, and 40 mg/mL) were assessed for viability and proliferation of hEnSCs during 24, 48, and 72 h using the MTT assay. The effect of the candidate microsphere 2.5 ng/mg (Mic EpoB) on hEnSCs was also evaluated by indirect MTT assay for 24, 48, and 72 h (Fig. 3j). The results indicated no cytotoxicity in all four PCL microsphere concentrations. For Mic EpoB, cell proliferation increased after 24 h. The Mic EpoB cell viability at 48 and 72 h after treatment was 94.1% (P < 0.01) and 76.5% (P < 0.001), respectively.

Cell morphology, attachment, and proliferation. Fluorescent microscopy. Collagen hydrogels improved adhesion and proliferation of HEK293-T (as a typical well-transected GFP cell) and hEnSCs-GFP. As shown in Figs. 4 and 5, the effect of hydrogel fabricated using 2 mg/mL collagen was more prominent on cell proliferation compared with hydrogel fabrication using 4 mg/mL collagen. Furthermore, among different

Figure 1. A schematic presentation of different steps of the study, including: EpoB microspheres synthesis using single emulsion, collagen extraction from rat tail, synthesis of collagen hydrogel and its crosslinking using proanthocyanidin from grape seed and calcium hydroxide (PA-CH), cell isolation, and culturing from human endometrium, and a three-step MN-differentiation (during 15 days).
groups, the 0.5% PA-CH hydrogel had the greatest cell proliferation compared to other PA-crosslinked collagen hydrogels in both 2 mg/mL and 4 mg/mL collagen concentrations (i.e., 2-Col/PA-CH and 4-Col/PA-CH). Since the 2-Col/PA-CH hydrogel had a more prominent effect on cell proliferation compared to 4-Col/PA-CH, this formulation was selected as the optimized hydrogel for further experiments.

**Figure 2.** Characterization of cell markers for hEnSCs and verification of GFP-labeling. (a) The results of flow cytometric assessment of hEnSCs at passage three, isolated from the endometrial biopsy. Dark red lines display isotype control (negative control). hEnSCs were positive for mesenchymal stem cell markers CD44 (98.5%), CD90 (98.4%), and CD105 (98.4%), endometrial stem cell marker CD146 (89.1%), shown as a right shift of the fluorescent intensity peak. hEnSCs were also negative for hematopoietic CD45, CD34, and endothelial CD31 markers (no shift of the fluorescent peak was observed). (b) HEK293-T and hEnSCs transduction with GFP-expressing lentiviral vectors. To confirm GFP expression, the labeled HEK293-T and hEnSCs were monitored with a fluorescent microscopy.

**Hydrogel biodegradation.** The degradation of different hydrogel formulations, including collagen, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB, during 14 days of incubation in DMEM-F12 medium at 37 °C was evaluated (Fig. 7a). The degradation degree of collagen hydrogel was higher than the other two groups (i.e., 2-Col/PA-CH and 2-Col/PA-CH/Mic EpoB). Adding of collagen-coated Mic EpoB and PA-CH as a cross-linker increased the stability of the collagen hydrogel. Furthermore, 2-Col/PA-CH/Mic EpoB showed slower degradation and higher stability compared with 2-Col/PA-CH.

**Hydrogel swelling.** The swelling degree of collagen, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB hydrogels in DMEM-F12 was calculated until 96 h (Fig. 7b). The swelling degrees were as follow:

- 2-Col/PA-CH/Mic Epo > collagen > 2-Col/PA-CH.
Figure 3. Characterization of microspheres. Scanning electron microscopy (SEM) and characterization of unloaded, 2.5, 10, and 40 ng/mg EpoB/PCL microspheres. (a–d) SEM shows smooth morphology and some microsphere clustering. (e–h) Particle size distribution histogram indicating expected particle size diameters (Sample size n = 100). (i) The cumulative release profile of 2.5, 10, and 40 ng/mg EpoB/PCL microspheres over 21 days (7-time points). Sample size n = 3. (j) The effect of 2.5 ng/mg EpoB Mic and different concentrations of PCL microspheres (unloaded Mic) on cell viability of hEnScs. Data are displayed as the percentage of cell viability in three independent tests, with each test having three individual samples. Cell viability graphs were compiled using SPSS 21 (clustered bar, summaries for groups of cases). (Error bars: ± 1 SD). P values were assessed with SPSS 21, using one-way ANOVA and DUNNETT test. The effect of all samples was compared to 0 (control). *P < 0.05, **P < 0.01, ***P < 0.001.

| EpoB concentration added | Encapsulation efficiency ± SD (%) |
|--------------------------|----------------------------------|
| 2.5 ng/mg EpoB/PCL      | 83 ± 1                           |
| 10 ng/mg EpoB/PCL       | 88.9 ± 0.5                       |
| 40 ng/mg EpoB/PCL       | 93.9 ± 0.3                       |

Table 7. Encapsulation efficiencies for different drug loading. Sample size n = 3, P < 0.001.
The results showed that adding PA-CH as cross-linker causes a decrease in the swelling degree of collagen. However, the addition of coated collagen microspheres to collagen gel increased the swelling degree of the hydrogel. The consistency in cross-linked collagen hydrogels is presented in Fig. 7c.

ATR-FTIR spectroscopy. The ATR-FTIR spectra of PA, collagen, 2-Col/PA, 2-Col/PA-CH are presented in Fig. 7d. The main peaks including amide A (3280–3290 cm⁻¹), amide B (3075–3085 cm⁻¹), amide I (1635–1656 cm⁻¹), amide II (1549–1566 cm⁻¹), amide III (1174–1177 cm⁻¹), aliphatic C–H bond (2925–2942 cm⁻¹), CH₂ bending (1397–1401 cm⁻¹) were detected and pointed out by arrows and dash lines. Additionally, to enhances the separation of overlapping peaks, second-derivative spectrum in the amide B region was achieved via irAnalyze software, showing secondary structure conformational changes in the two cross-linked hydrogels scaffold (2-Col/PA and 2-Col/PA-CH) compared to the collagen (uncross-linked) hydrogel scaffold (Fig. 7e).

The effect of 3D collagen hydrogel and EpoB release on differentiation of hEnSCs into motor neuron-like cells. Immunofluorescence staining. After 15 days of MN-induction, the morphology of hEnSCs changed from a fibroblast-like shape to a bipolar and round cell body shape with neurites. The neuron-like morphology was observed using an inverted phase-contrast microscope (Olympus, Japan). IF staining results showed up-regulation of the MN markers ISL-1, CHAT, and HB9 in all three experimental groups, but no expression in the control group (Fig. 8a).

Differentiation rate was investigated by counting each positive cell marker (beta-tubulin III, ISL-1, CHAT, NES, HB9) as a percentage of the total number of DAPI-stained cells. The level of positive MN markers expression in cells seeded on 2-Col/PA-CH/Mic EpoB group was significantly higher (P < 0.001) than the other two groups (i.e., TCP, and 2-Col/PA-CH), except for NES. The positive marker expression of different evaluated markers in TCP, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB is shown below, respectively. Quantitative results are also shown in Fig. 8b.

- beta-tubulin III (89%, 92%, 98%)
- ISL-1 (83%, 88%, 98%)
- CHAT (80%, 85%, 97%)
Figure 5. Adhesion and proliferation of hESCs-GFP within collagen hydrogels before and after cross-linking using different concentrations of PA (0.25% PA, 0.5% PA, and 0.5% PA-CH). (a) Collagen hydrogels were fabricated using 2 mg/mL collagen with or without Mic EpoB at day 1 and day 6. (b) and a comparison between hydrogels was performed using different collagen concentrations (i.e., 2 mg/mL and 4 mg/mL) with or without Mic EpoB at day 6 of culture.
Figure 6. Cell attachment and surface morphology of different collagen hydrogel groups. Scanning electron micrographs of hEnSCs attachment on (a) collagen, (b) 2-Col/PA-CH, and (c) 2-Col/PA-CH/Mic EpoB hydrogels 48 h after cell seeding. Micrographs show hydrogel with cells at ×1000 and ×3000 magnifications (pseudo-colored). Scanning electron micrographs of different collagen hydrogel groups (d–h) indicates their surface morphology and interconnected porosity: 2-Col/PA-CH/Mic EpoB (d,e), collagen (f), 2-Col/PA (g), and 2-Col/PA-CH (h). EpoB microspheres were detected in the 2-Col/PA-CH/Mic EpoB hydrogel (d,e). Moreover, the cell attachment (highlighted in yellow) and EpoB microspheres (pointed with red arrows) are displayed in 2-Col/PA-CH/Mic EpoB hydrogel in Figure e.
After 15 days of cell induction, real-time RT-PCR was performed to compare the fold-change of RNA expressions of HB9, ISL-1, NES, and NEFH in three experimental groups, including TCP, 2-Col/PA-CH, 2-Col/PA-CH/Mic EpoB and control (undifferentiated hEnSCs) (Fig. 8c). The real-time-RT-PCR results indicated that the level of HB9, ISL-1, NES, and NEFH was significantly up-regulated in all three induced hEnSCs groups (P < 0.001, P < 0.01). Between the three experimental groups, the 2-Col/PA-CH/Mic EpoB hydrogel had the highest expression level of HB9 and ISL-1 as MN markers (12.4- and 12-fold change, respectively). The expression of HB9 in the 2-Col/PA-CH/Mic EpoB hydrogel was 4.43- and 4.13-times higher than the TCP and 2-Col/PA-CH hydrogel, respectively (2.8- and 3-fold change, respectively). The expression of ISL-1 in the 2-Col/PA-CH/Mic EpoB hydrogel was 2.4- and 1.71-times higher than the TCP and 2-Col/PA-CH hydrogel, respectively.

**Figure 7.** Degradation and swelling degree, and ATR-FTIR spectra of different collagen hydrogel groups. (a) Degradation and (b) swelling degree of collagen, 2-Col/PA-CH (Cross-linked 2 mg/collagen hydrogel with 0.5% proanthocyanidin and calcium hydroxide), and 2-Col/PA-CH/Mic EpoB (Cross-linked 2 mg/mL collagen hydrogel with 0.5% proanthocyanidin and calcium hydroxide and 2.5 ng/mL Epo B microspheres) hydrogels in DEME-F12 at 37 °C (The time duration: 14 days for degradation test and 4 days for swelling test). *P < 0.05, **P < 0.01, ***P < 0.001. (c) The consistency in cross-linked collagen hydrogels. (d) The ATR-FTIR spectra of PA, collagen, 2-Col/PA, 2-Col/PA-CH and, (e) their second-derivative spectra in the amide B region. The main peaks are shown by red arrows and gray dash lines. The second-derivative spectra in the amide B region indicate secondary structure conformational changes in the two cross-linked hydrogels scaffold (2-Col/PA and 2-Col/PA-CH) compared to the collagen (uncross-linked) hydrogel scaffold.

- NES (100%, 100%, 100%)
- HB9 (78%, 84%, 96%)

**Molecular analysis using real-time-PCR.** After 15 days of cell induction, real-time RT-PCR was performed to compare the fold-change of RNA expressions of HB9, ISL-1, NES, and NEFH in three experimental groups, including TCP, 2-Col/PA-CH, 2-Col/PA-CH/Mic EpoB and control (undifferentiated hEnSCs) (Fig. 8c). The real-time-RT-PCR results indicated that the level of HB9, ISL-1, NES, and NEFH was significantly up-regulated in all three induced hEnSCs groups (P < 0.001, P < 0.01). Between the three experimental groups, the 2-Col/PA-CH/Mic EpoB hydrogel had the highest expression level of HB9 and ISL-1 as MN markers (12.4- and 12-fold change, respectively). The expression of HB9 in the 2-Col/PA-CH/Mic EpoB hydrogel was 4.43- and 4.13-times higher than the TCP and 2-Col/PA-CH hydrogel, respectively (2.8- and 3-fold change, respectively). The expression of ISL-1 in the 2-Col/PA-CH/Mic EpoB hydrogel was 2.4- and 1.71-times higher than the TCP and 2-Col/PA-CH hydrogel, respectively.
Figure 8. The expression of MN-like cells differentiated from hEnSCs in different groups. (a) Immunofluorescence images of MN-like differentiated hEnSCs in different groups of TCP, collagen hydrogel without Mic EpoB (2-Col/PA-CH/M), collagen hydrogel with Mic EpoB (2-Col/PA-CH/Mic EpoB), and control (undifferentiated hEnSCs) for beta-III-tubulin, NES, ISL-1, CHAT, and HB9 after 15 days (× 20, Scale bar 100 μm). (b) Expression (ratio of positive cells, %) of MN markers calculated from three wells (five fields per well). (c) Relative gene expression in three differentiated groups, including TCP, Col without Mic EpoB, Col with Mic EpoB, and control (undifferentiated hEnSCs) after 15 days for NEFH, ISL-1, NES, and HB9. Graphs were generated with SPSS 21 (simple bar, summaries for groups of cases). Data were presented as three independent experiments. (Error bars: ± 1 SD). The p-values were assessed using SPSS 21, one-way ANOVA, and the DUNNETT test. In part B: Col without Mic EpoB and Col with Mic EpoB groups were compared with TCP: *P < 0.05, **P < 0.01, ***P < 0.001. In part C: The effects of three differentiation groups (TCP, col-without Mic EpoB, and col-with Mic EpoB) compared with control group (undifferentiated hEnSCs): *P < 0.05, **P < 0.01, ***P < 0.001.
PA-CH, respectively (5- and 7-fold change, respectively). The NES and NEFH expressions in the 2-Col/PA-CH/Mic EpoB hydrogel were almost the same as TCP and 2-Col/PA-CH groups.

### Discussion

In recent years, increasing evidence suggests that small molecules are effective chemical agents for cell survival and differentiation, and may be candidates for various interventional therapies\(^6^0\). Small molecules often regulate the activity of several transcription factors, which can thereby determine cell fate. Thus, exposing stem cells to small molecules can advance cell differentiation by mimicking tissue microenvironment during organogenesis\(^6^1,6^2\). Ruschel et al. reported low doses of EpoB, known as a small molecule, diminishes fibrotic scar tissue and induces axonal regeneration in vitro in injured cortical neurons of postnatal rats\(^3^7\). This study aimed to evaluate the effect of sustained release of EpoB using PCL microspheres embedded in 3D collagen hydrogel for differentiation of hEnSCs into MN-like cells.

Many studies have proposed tissue engineering as a practical approach to repairing various damaged tissues, and nerve tissue engineering is no exception to this rule, especially given the increasing rate of SCI\(^2^3,6^3\). Many combinational approaches have proven advantageous compared with using each method separately. However, these approaches require further elucidation to ensure a meaningful effect compared to their individual usage\(^1^2\).

It is known that ECMs have active roles in cell survival, neuronal differentiation, and neurite development\(^4^2\). Embedding hydrogels alone without any treatment may slightly improve injury outcomes after SCI\(^1^\). However, for the hydrogel approach, it has been shown drug incorporation into hydrogels is necessary for effective healing of the injured environment\(^4^0,6^4\).

In this study, we synthesized EpoB/PCL microspheres to have a sustained release during the MN differentiation process. The results indicated that PCL microspheres mediated the sustained release of EpoB as a microtubule-stabilizing small molecule that enhances differentiation of hEnSCs to MN-like cells and increases axonal elongation. The addition of released EpoB, along with the differentiation protocol, promoted neurite outgrowth.

---

**Figure 9.** Neuronal morphology and neurite outgrowth. (a) Immunofluorescence images indicate neuronal morphology and neurite elongation of MN-like differentiated hEnSCs after 15 days of induction in collagen hydrogel with Mic EpoB (2-Col/PA-CH/Mic EpoB) group. (b) Neurite elongation is shown with red arrows. To display morphology, cells were stained using primary anti-beta III tubulin antibody and secondary Alexa Fluor 488 antibody (× 20 and × 40; Scale bar 100 μm). Neurite length of MN-like cells in 2-Col/PA-CH/Mic EpoB hydrogel compared to TCP and 2-Col/PA-CH differentiation groups at day 15 after differentiation (***P < 0.001).
and neuronal morphology. It also significantly increased the efficiency of motor neuron generation (796%), and compared to most recent studies, it gained a higher percentage of motor neurons 74,64,65.

PCL was chosen for microsphere synthesis because of its good biocompatibility, low biodegradation, and cost-effectiveness 76. All four groups of EpoB/PCL microspheres (0, 2.5, 10, and 40 ng/mg) were synthesized using a single emulsion technique, and their round shape microspheres with a smooth surface were demonstrated by SEM. Based on the EpoB release test results, the 2.5 ng/mg EpoB/PCL microsphere group was selected for MN differentiation given a more appropriate dose and drug release and normal size distribution. The indirect MTT test also confirmed the suitability of 2.5 ng/mg EpoB/PCL microsphere for our purposes with cell viability >77% after 72 h.

Recent studies indicate that culturing stem cells in 3D hydrogels improves cell maintenance, expansion, and differentiation by mimicking the native ECM66,67. For neuronal replacement therapies, given that neurons are not capable of dividing, stem cell expansion with hydrogel assistance is essential to achieve a suitable cell number before neuronal differentiation 68.

Cell attachment to the ECM is crucial for cell differentiation and proliferation via cell anchoring and activation of signaling pathways that can lead to tissue regeneration and development 69–71. Collagen is a key component of the ECM and is extensively used as a scaffold for its effective properties of improving cell attachment, survival, proliferation, differentiation, and migration 72. One study also reported that collagen might promote higher survival, adhesion, and proliferation of mesenchymal stem cells 73. These cell processes are regulated by the interaction of collagen with integrins in cell surface receptors 74. Moreover, collagen has garnered attention as a delivery system for the sustained release of different drugs and chemical agents 75,76.

GFP cell culture in the two collagen hydrogel concentrations (2 and 4 mg/mL) presented a dose-dependent proliferation of hEnSC. The lower concentration, 2 mg/mL, was selected because of its greater potential for cell proliferation and cell connection, which are important for neural differentiation. In line with our study, a previous report indicated that lower concentrations of collagen are more appropriate for neuronal differentiation and neurite outgrowth 77.

Moreover, adding either PA-CH or PA to the collagen hydrogel increased its stability during the 15-day differentiation process by decreasing the hydrogel’s degradation degree. However, hydrogels cross-linked with PA-CH showed a greater cell proliferation than PA alone. In addition, cross-linking the collagen hydrogel also decreased the swelling degree of the hydrogel. Interestingly, the 2-Col/PA-CH/Mic EpoB had a slower degradation degree than the collagen and 2-Col/PA-CH groups, which can be attributed to the interactions between PCL microspheres and the collagen hydrogel. The 2-Col/PA-CH/Mic EpoB had a higher swelling ratio than the collagen and 2-Col/PA-CH hydrogels. All three groups showed interconnected porous, proper cell-scaffold integration and cell attachment.

Immunofluorescence staining indicated that the beta III-tubulin marker was increased in all three differentiation groups (i.e., TCP, 2-Col/PA-CH, and 2-Col/PA-CH/Mic EpoB). In agreement with previous reports, undifferentiated hEnSCs and other sources of human MSCs have a spontaneous expression of this marker 78, demonstrating that it is possible for MSCs such as hEnSCs to undergo neuronal differentiation. Furthermore, other studies have shown that hEnSCs can induce spinal motor neuron generation during development by up-regulating dopamine 79. However, compared to the differentiation groups, the undifferentiated hEnSCs in our study had a lower beta III-tubulin expression. hEnSCs also spontaneously express NES. Thus, both NES and beta III-tubulin markers show hEnSCs to be a suitable source for neuronal differentiation and spinal cord restoration.

Real-time RT-PCR determined significant gene up-regulation of NEFH, NES, ISL-1, and HB9 after 15 days of induction. Higher gene expression of ISL-1 and HB9 in the 2-Col/PA-CH/MicEpoB group compared to the other two differentiation groups showed that incorporation of EpoB microspheres in the collagen hydrogels may significantly increase the MN differentiation efficacy of hEnSCs.

The results show that the release of EpoB from microspheres, in addition to RA and SHH, increase HB9 gene expression 80,81, and can significantly enhance the gene expression of HB9 and also ISL-1, which are two crucial regulators of mature motor neurons 82,83. Moreover, among the other two groups, the 2-Col/PA-CH group demonstrated higher ISL-1 gene expression.

The percentage of HB9 and ISL-1 positive cells is known to be an indicator of motor neuron differentiation efficiency 84. The three differentiation groups, 2-Col/PA-CH/Mic EpoB, 2-Col/PA-CH, and TCP, demonstrated 94%, 84%, and 78% HB9 positive cells, while this was 98%, 88%, and 83% for ISL-1, respectively. This confirms the higher MN-differentiation efficiency of the 2-Col/PA-CH/Mic EpoB group compared to the other two differentiation groups. This is while a previous study indicated 11.7% and 23.7% positive cells for HB9 and ISL-1, respectively, for MN-like cells derived from tonsil mesenchymal stem cells (T-MSCs). Also, other studies show 35–46% and 70–90% positive cells for HB9 and ISL-1, respectively, in MN-like cells derived from induced pluripotent stem cells (iPSCs) 85–87.

Furthermore, the neurite length of MN-like cells in the 2-Col/PA-CH/Mic EpoB group increased remarkably to 146 μm, which is more than three times longer compared to the other two groups without Epo B microspheres (2-Col/PA-CH, and collagen groups). Recently, it was reported that acellularized spinal cord scaffolds incorporating bpV(pic)/PLGA microspheres promote axonal regeneration by about 45μm 88.

Another study indicated that adding 3 mM of paclitaxel as an MSA can enhance neurite length of mature rat retinal ganglion cells (RGs) by 40 μm while using 10 mM paclitaxel significantly decreases neurite outgrowth 89. This shows that paclitaxel has less of an effect on neurite outgrowth than EpoB. Additionally, compared with paclitaxel, EpoB has a smaller molecular size, higher solubility, and the capability to pass the blood–brain barrier (BBB) 90,91. It is worth noting that EpoB can be effective for axon elongation and MN-differentiation, despite the presence of the neurite outgrowth inhibitor A, which is known to be an axonal inhibitor in SCI92,93.

One proposed method of increasing neurite outgrowth in recent years is electrical stimulation 94–96. A study reported that the neurite length of PC12 cells via gold-nanoparticle after electrical stimulation (ES) was 120 μm 97.
Another study reported, the final neurite length of the primary prefrontal cortex (PFC) in collagen 3D cultures with E5 to be ~110 µm, compared to the control wild-type where only ~10 µm of elongation was observed. Thus, our results indicate that the fabricated 2-Col/PA-CH/Mic EpoB hydrogel achieved a higher neurite elongation than in the mentioned studies.

While understanding the exact mechanism of EpoB and adapting it to the complex mechanism of SCI yet need to achieve a clear vision, today its role in stem cell differentiation and SCI has garnered attention, and our study demonstrated the enhanced MN differentiation efficiency of hEnSCs and neurite growth by 3D cross-linked collagen hydrogel containing EpoB-loaded microspheres which can be used as a combinatorial approach for MN-diseases modeling and a future aid in SCI repair.

Conclusion
To our knowledge, this is the first time that ultra-low doses of EpoB loaded microspheres have been synthesized for the purpose of MN differentiation from hEnSCs. Our study demonstrates that incorporation of EpoB microspheres with collagen hydrogel can significantly increase the MN differentiation efficiency of hEnSCs by up-regulating ISL-1 and HB9, known as mature motor neuron key markers. Moreover, our results showed that the addition of EpoB microspheres significantly enhances neurite growth during MN differentiation. Utilizing proanthocyanidin and calcium hydroxide as cross-linkers significantly reduces the degradation degree of the 3D collagen hydrogel and provides an appropriate stable ECM for supporting cell attachment, proliferation, and differentiation. Our findings emphasize the active role that 3D cross-linked collagen hydrogels containing EpoB-loaded microspheres for nerve tissue engineering and the potential of using combinatorial approaches to overcome the limitations of individual methods for SCI repair.

Data availability
The datasets used and/or analyzed during the current study are available on reasonable request.

Received: 19 July 2021; Accepted: 22 October 2021
Published online: 05 November 2021

References
1. Izazery, S. B., Beygi, S., Shokraneh, F., Hagen, E. M. & Rahimi-Movaghar, V. Incidence of traumatic spinal cord injury worldwide: A systematic review. Eur. Spine J. 24, 905–918 (2015).
2. James, S. L. et al. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 56–87 (2019).
3. Hassannejad, Z. et al. Axonal degeneration and demyelination following traumatic spinal cord injury: A systematic review and meta-analysis. J. Chem. Neuroanat. 97, 9–22 (2019).
4. Johnson, P. J., Tatara, A., Shiu, A. & Sakiyama-Elbert, S. E. Controlled release of neurotrophin-3 and platelet-derived growth factor from fibrin scaffolds containing neural progenitor cells enhances survival and differentiation into neurons in a subacute model of SCI. Cell Transplant. 19, 89–101 (2010).
5. Nikkabht-Nasrabadi, A., Mohammadi, N., Yazdanshenas, M. & Shabany, M. Toward overcoming physical disability in spinal cord injury: A qualitative inquiry of the experiences of injured individuals and their families. BMC Neurol. 19, 1–8 (2019).
6. Noorimostagh, Z., Babaie, M., Safdarian, M., Ghadiri, T. & Rahimi-Movaghar, V. Mechanisms of spinal cord injury regeneration in zebrash. A systematic review. Iran. J. Basic Med. Sci. 20, 1287 (2017).
7. Rolls, A., Shechter, R. & Schwartz, M. The bright side of the glial scar in CNS repair. Nat. Rev. Neurosci. 10, 235 (2009).
8. Johnson, C. D., D’Amato, A. R. & Gilbert, R. J. Electrospray fibers for drug delivery after spinal cord injury and the effects of drug incorporation on fiber properties. Cells Tissues Organs 202, 116–135 (2016).
9. Shabany, M. et al. Reliability and validity of the Persian version of the spinal cord injury lifestyle scale and the health behavior questionnaire in persons with spinal cord injury. Spinal Cord 56, 509–515 (2018).
10. Gao, S. et al. Differentiation of human adipose-derived stem cells into neuron/motoneuron-like cells for cell replacement therapy of spinal cord injury. Cell Death Dis. 10, 1–15 (2019).
11. Hassannejad, Z. et al. The fate of neurons after traumatic spinal cord injury in rats: A systematic review. Iran. J. Basic Med. Sci. 21, 546 (2018).
12. Griffin, J. M. & Bradke, F. Therapeutic repair for spinal cord injury: Combinatory approaches to address a multifaceted problem. EMBO Mol. Med. 12, e11505 (2020).
13. Farzin, A. et al. A facile two step heat treatment strategy for development of bioceramic scaffolds for hard tissue engineering applications. Mater. Sci. Eng. C 105, 110009 (2019).
14. Khanmohammadi, M., Nemati, S., Ai, J. & Khademi, F. Multipotency expression of human adipose stem cells in filament-like alginate and gelatin derivative hydrogel fabricated through visible light-initiated crosslinking. Mater. Sci. Eng. C 103, 109808 (2019).
15. Bordbar, S. et al. Production and evaluation of decellularized extracellular matrix hydrogel for cartilage regeneration derived from knee cartilage. J. Biomed. Mater. Res. Part A 108, 938–946 (2020).
16. Astaneh, M. E. et al. Chitosan/gelatin hydrogel and endometrial stem cells with subsequent atorvastatin injection impact in regenerating spinal cord tissue. J. Drug Deliv. Sci. Technol. https://doi.org/10.1016/j.jddst.2020.101831 (2020).
17. Zahiri, M. et al. Encapsulation of curcumin loaded chitosan nanoparticle within poly (ε-caprolactone) and gelatin fiber mat for wound healing and layered dermal reconstruction. Int. J. Biol. Macromol. 153, 1241–1250 (2019).
18. Hasanzadeh, E. et al. Preparation of fibrin gel scaffolds containing MWCNT/PU nanofibers for neural tissue engineering. J. Biomed. Mater. Res. Part A 107, 802–814 (2019).
19. Jalali Mondared, M. et al. Transplantation of miR-219 overexpressed human endometrial stem cells encapsulated in fibrin hydrogel in spinal cord injury. J. Cell. Physiol. 234, 18887–18896 (2019).
20. Hasanzadeh, E. et al. Defining the role of 17β-estradiol in human endometrial stem cells differentiation into neuron-like cells. Cell Biol. Int. 45, 140–153 (2021).
21. Shirian, S. et al. Comparison of capability of human bone marrow mesenchymal stem cells and endometrial stem cells to differentiate into motor neurons on electrospray poly (ε-caprolactone) scaffold. Mol. Neurobiol. 53, 5278–5287 (2016).
22. Jin, M. C., Medress, Z. A., Azad, T. D., Doulames, V. M. & Veeravagu, A. Stem cell therapies for acute spinal cord injury in humans: A review. Neurosurg. Focus 46, E10. https://doi.org/10.3171/2018.12.focus18602 (2019).
23. Zavvarian, M.-M., Toossi, A., Khazaei, M., Hong, J. & Felhings, M. Novel innovations in cell and gene therapies for spinal cord injury. Frontiers Research 9, 1–11 (2020).
24. Rauck, B. M., Novosat, T. L., Oudega, M. & Wang, Y. Biocompatibility of a coacervate-based controlled release system for protein delivery to the injured spinal cord. Acta Biomater. 11, 204–211 (2015).
25. Tosolini, A. P. & Sleigh, J. N. Motor neuron gene therapy: Lessons from spinal muscular atrophy for amyotrophic lateral sclerosis. Front. Mol. Neurosci. 10, 405 (2017).
26. Mahmoudi, N. et al. Microtubule stabilizer epothilone B as a motor neuron differentiation agent for human endometrial stem cells. Cell Biol. Int. 44, 1168–1183 (2020).
27. Demers, C. J., Cox, G., Collins, S. D. & Smith, R. L. in 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 477–480 (IEEE).
28. Schenk, M., Schjeide, B.-M., Püschel, G. P. & Seeger, B. Analysis of motor neurons differentiated from human induced pluripotent stem cells for the use in cell-based botulinum neurotoxin activity assays. Toxins (Basel) 12, 276 (2020).
29. Kaptein, L. C. & Hoogenraad, C. C. Building the neuronal microtubule cytoskeleton. Neuron 87, 492–506 (2015).
30. Dent, E. W. & Baas, P. W. Microtubules in neurons as information carriers. J. Neurochem. 129, 235–239 (2014).
31. Jang, E. H. & Sim, A. Effects of microtubule stabilization by epothilone B depend on the type and age of neurons. Neural Plast. 2016, 2056418 (2016).
32. Erturk, A., Hellal, F., Enes, J. & Bradke, F. Disorganized microtubules underlie the formation of retraction bulbs and the failure of axonal regeneration. J. Neurosci. 27, 9169–9180. https://doi.org/10.1523/jneurosci.0612-07.2007 (2007).
33. Bonini, S. A., Mastina, A., Ferrari-Toninelli, G. & Memo, M. Potential role of microtubule stabilizing agents in neuromuscular disorders. Int. J. Mol. Sci. 18, 1627 (2017).
34. Baas, P. W., Rao, A. N., Matamoros, A. J. & Leo, L. Stability properties of neuronal microtubules. Cytoskeleton 73, 442–460 (2016).
35. Varidaki, A., Hong, Y. & Coffey, E. T. Repositioning microtubule stabilizing drugs for brain disorders. Front. Cell. Neurosci. 12, 226 (2018).
36. Forli, S. Epothilones: From discovery to clinical trials. Curr. Top. Med. Chem. 14, 2321–2324 (2014).
37. Ruschel, J. et al. Axonal regeneration. Systemic administration of epothilone B promotes axon regeneration after spinal cord injury. Science (New York, N.Y.) 348, 347–352. https://doi.org/10.1126/science.aaa2958 (2015).
38. Zhao, W. et al. Mechanisms responsible for the inhibitory effects of epothilone B on scar formation after spinal cord injury. Neuronal Regen. Res. 12, 478 (2017).
39. Gomez, J. C. et al. Incorporation of retinoic acid releasing microspheres into pluripotent stem cell aggregates for inducing neuronal differentiation. Cell. Mol. Biol. 8, 307–319 (2015).
40. Assunção-Silva, R. C., Gomes, E. D., Sousa, N., Silva, N. A. & Salgado, A. J. Hydrogels and cell based therapies in spinal cord injury regeneration. Stem Cells Int. https://doi.org/10.1155/2015/948040 (2015).
41. Ghorbani, M. et al. Injectable natural polymer compound for tissue engineering of intervertebral disc: In vitro study. Mater. Sci. Eng. C 80, 502–508 (2017).
42. Reis, R. L. et al. Natural-Based Polymers for Biomedical Applications (Elsevier, 2008).
43. Gorgievsa, S. & Kokol, V. Collagen-vs. gelatin-based biomaterials and their biocompatibility: Review and perspectives. Biomater. Appl. Nanomed. 2, 17–52 (2011).
44. Entekhabi, E. et al. Fabrication and in vitro evaluation of 3D composite scaffold based on collagen/hyaluronic acid sponge and electrospun PCL nanofibers for peripheral nerve regeneration. J. Biomater. Res. Part A 109, 300–312 (2020).
45. Lee, C. H., Singla, A. & Lee, Y. Biomedical applications of collagen. Int. J. Pharm. 211, 1–22 (2001).
46. Schneider-Barthold, C., Baganz, S., Wilhelm, M., Scheper, T. & Pelapalova, I. Hydrogels based on collagen and fibrin–fibrinogen and applications. BioNanoMaterials 17, 3–12 (2016).
47. Rights are reserved by Raju, A. & Asole, J. An Overview on Polyethylene Glycol Gelation for Anti-Cancer Activity. Adv. Drug Deliv. Rev. 144, 33–37 (2019).
48. Shu, X. Z., Liu, Y., Palumbo, F. S., Luo, Y. & Prestwich, G. D. In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25, 1339–1348 (2004).
49. Fathi, A. et al. Fabrication of chitosan-polyvinyl alcohol and silk electrospun fiber seeded with differentiated keratinocyte for skin tissue regeneration in animal wound model. J. Biol. Eng. 14, 1–14 (2020).
50. Yoshi, S. S., Kukszynski, C. & Bagchi, D. The cellular and molecular basis of health benefits of grape seed proanthocyanidin extract. Curr. Pharm. Biotechnol. 2, 187–200 (2001).
51. Fine, A. M. Oligomeric proanthocyanidin complexes: History, structure, and phytopharmaceutical applications. Altern. Med. Rev. 14, 5 (2000).
52. Han, B., Jaurequi, I., Tang, B. W. & Nimni, M. E. Proanthocyanidin: A natural crosslinking reagent for stabilizing collagen matrices. J. Biomed. Mater. Res. Part A 65, 118–124 (2003).
53. Hennink, W. E. & van Nostrum, C. F. Novel crosslinking methods to design hydrogels. Adv. Drug Deliv. Rev. 64, 223–236 (2012).
54. Ma, B., Wang, X., Wu, C. & Chang, J. Crosslinking strategies for preparation of extracellular matrix derived cardiovascular scaffolds. Regen. Biomater. 1, 81–89 (2014).
55. Hasanzadeh, E. et al. Proanthocyanidin as a crosslinking agent for fibrin, collagen hydrogels and their composites with decellularized Wharton’s-jelly-extract for tissue engineering applications. J. Bioact. Compat. Polym. 35(6), 554–571 (2020).
56. At, I. et al. Derivation of adipocytes from human endometrial stem cells (EnSCs). J. Reprod. Infertil. 13, 151–157 (2012).
57. Zarei-Behjani, Z. et al. Tracking of GFP-labeled unrestricted somatic stem cells transplanted in the sepsis mouse model. Tissue Cell 60, 33–37 (2019).
58. Mahmoudi, N. et al. Are reported methods for synthesizing nanoparticles and microparticles by magnetic stirrer reproducible?. I. Comput. Appl. Mech. 51, 498–500 (2020).
59. Rajan, N., Habermehl, J., Coté, M.-F., Duillier, C. I. & Mantovani, D. Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications. Nat. Protoc. 1, 2753 (2006).
60. Ebrahimi-Barough, S. et al. Inhibitor of PI3K/Akt signaling pathway small molecule promotes motor neuron differentiation of human endometrial stem cells cultured on electrospun biocomposite polycaprolactone/collagen scaffolds. Mol. Neurobiol. 54, 2547–2554 (2017).
61. George, S., Hamblin, M. R. & Abrahamsson, H. Differentiation of mesenchymal stem cells to neuroglia: In the context of cell signalling. Stem Cell Res. Rep. 15, 814–826 (2019).
62. Rodriguez-Martinez, J. A., Peterson-Kaufman, K. J. & Ansari, A. Z. Small-molecule regulators that mimic transcription factors. Biochim. Biophys. Acta 1799, 768–774 (2010).
63. Jahromi, H. K. et al. Enhanced sciatic nerve regeneration by poly-L-lactic acid/multi-wall carbon nanotube neural guidance conduit containing Schwann cells and curcumin encapsulated chitosan nanoparticles in rat. Mater. Sci. Eng. C 109, 110564 (2020).
64. Trawczynski, M., Liu, G., David, B. & Peskner, R. G. Restoring motor neurons in spinal cord injury with induced pluripotent stem cells. Front. Cell. Neurosci. 13, 369 (2019).
65. Maury, Y. et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 33, 89–96 (2015).
66. Madl, C. M., Katz, L. M. & Heilshorn, S. C. Tuning bulk hydrogel degradation by simultaneous control of proteolytic cleavage kinetics and hydrogel network architecture. ACS Macro Lett. 7, 1302–1307 (2018).
67. Madl, C. M. et al. Maintenance of neural progenitor cell stemness in 3D hydrogels requires matrix remodelling. Nat. Mater. 16, 1233–1242 (2017).
This work was supported by Sina Trauma and Surgery Research Center, Tehran University of the Medical Sciences (Grant number: 30424-38-03-94) and is part of a Ph.D. thesis of the first author (NM) under the supervision of VRM and JA to achieve the Ph.D. of Tissue Engineering from Tehran University of Medical Sciences (The thesis/contract number 9311598022 in the date 2016-11-5).

Acknowledgements
The authors would like to thank Dr. Zeinab Zarei-Behjani for her kind help and technical assistance for hEnSCs GFP labeling.

Author contributions
This work is part of a Ph.D. thesis of the first author (NM) under the supervision and support of VRM and JA to achieve the Ph.D. of Tissue Engineering from Tehran University of Medical Sciences (The thesis/contract number 9311598022 in the date 2016-11-5). NM did all the techniques, analysis, interpretation of the data and manuscript drafting. Z.H. and S.E. were the advisors for this work. They greatly facilitate laboratory work and troubleshooting. E.H. helped to isolate and culture stem cells from biopsy. Moreover, V.R.M., Z.H., S.E., E.H. and H.N. edited the manuscript from different aspects. A.V. as an expert and native English speaker edited the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by Sina Trauma and Surgery Research Center, Tehran University of the Medical Sciences (Grants number: 30424-38-03-94) and is part of a Ph.D. thesis of the first author (NM) under the supervision of VRM and JA to achieve the Ph.D. of Tissue Engineering from Tehran University of Medical Sciences (The thesis/contract number 9311598022 in the date 2016-11-5).
Competing interests
Alexander R. Vaccaro is a board member of AOSpine, Innovative Surgical Design, Association of Collaborative Spine Research, DePuy; Consultant at Medtronics, Stryker Spine, Globus, Stout Medical, Gerson Lehrman Group, Guidepoint Global, Medacorp, Innovative Surgical Design, Orthobullets, Ellipse, Vertex, Medtronics; Royalty at Stryker Spine, Biomet Spine, Globus, Aesculap, Thieme, Jaypee, Elsevier, Taylor Francis. All remaining authors declare that they have no financial or non-financial/personal conflict exists and also no commercial associations that might pose a conflict of interest in connection with the submitted article.

Additional information
Correspondence and requests for materials should be addressed to V.R.-M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021